Nick Brazeau
About
Research
Pubs & Talks
Blog
CV
Contact
daptomycin
Loss of daptomycin susceptibility in clinical Staphylococcus epidermidis infection coincided with variants in WalK
Daptomycin (DAP) is key in treating multidrug-resistant Staphylococcus infections. Diminished susceptibility to DAP is emerging among Staphylococcus epidermidis strains although mechanisms for non-susceptibility (NS) remain poorly understood. We …
Cite
×